Curevac, a Germany-based biotechnology company backed by pharmaceutical firm Boehringer Ingelheim, has added $29.5m to a funding round that now totals almost $140m.
The tranche was co-led by LBBW Asset Management Investmentgesellshaft, part of public pension fund Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte (BWVA), and state-owned financial services firm Landeskreditbank Baden-Württemberg.
The capital adds to a $110m initial tranche closed in November 2015 that was led by Baillie Gifford and backed by Chartwave, Coppel Family, Northview, Sigma Group, Dievini…
